{"id":916054,"date":"2025-12-03T19:09:29","date_gmt":"2025-12-04T00:09:29","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/berger-montague-pc-investigating-claims-on-behalf-of-skye-bioscience-inc-nasdaq-skye-investors-after-class-action-filing\/"},"modified":"2025-12-03T19:09:29","modified_gmt":"2025-12-04T00:09:29","slug":"berger-montague-pc-investigating-claims-on-behalf-of-skye-bioscience-inc-nasdaq-skye-investors-after-class-action-filing","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/berger-montague-pc-investigating-claims-on-behalf-of-skye-bioscience-inc-nasdaq-skye-investors-after-class-action-filing\/","title":{"rendered":"Berger Montague PC Investigating Claims on Behalf of Skye Bioscience, Inc. (NASDAQ: SKYE) Investors After Class Action Filing"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n
\n PHILADELPHIA<\/span>
\n <\/span>, Dec. 3, 2025<\/span><\/span> \/PRNewswire\/ — National plaintiffs’ law firm Berger Montague PC<\/span><\/a><\/u>\u00a0announces that a class action lawsuit has been filed against Skye Bioscience, Inc. (NASDAQ: SKYE)<\/b> (“Skye” or the “Company”) on behalf of investors who purchased or otherwise acquired Skye securities during the period of\u00a0November 4, 2024<\/span> through October 3, 2025<\/span><\/b>(the “Class Period”), inclusive.<\/p>\n

\n

\n
\n \"A
\n <\/a>\n <\/p>\n<\/p><\/div>\n

\n
\n Investor Deadline:<\/i>
\n <\/b>
\n Investors who purchased Skye\u00a0securities during the Class Period may, no later than January 16, 2026<\/span><\/b>, seek to be appointed as a lead plaintiff representative of the class. To learn your rights,<\/i>\u00a0CLICK HERE<\/a><\/u><\/b>.<\/p>\n

Skye, headquartered in San Diego<\/span>, is a clinical-stage biotechnology company developing treatments for obesity and metabolic diseases.<\/p>\n

The complaint asserts that, throughout the Class Period, Defendants failed to disclose that: (i) the efficacy of nimacimab, Skye’s lead product candidate, was lower than what had been represented to investors; and (ii) as a result, the drug’s clinical and commercial potential had been overstated.<\/p>\n

On October 6, 2025<\/span>, Skye issued a press release announcing topline data from its 26-week Phase 2a CBeyond proof-of-concept study of nimacimab, disclosing that that the primary endpoint of 8% difference in weight loss compared to placebo had not been met. Following these disclosures, Skye’s stock price declined $2.85<\/span> per share, or 60%<\/b>, closing at $1.90<\/span> on October 6, 2025<\/span>.<\/p>\n

\n
\n If you are a Skye investor and would like to learn more about this action, <\/i>
\n <\/b>
\n
\n
\n
\n CLICK HERE<\/a>
\n <\/u>
\n <\/i>
\n <\/b>\u00a0or please contact Berger Montague<\/span>: Andrew Abramowitz<\/span> at <\/i><\/b>aabramowitz@bergermontague.com<\/a><\/u><\/i><\/b> or (215) 875-3015, or Caitlin Adorni<\/span> at <\/i><\/b>cadorni@bergermontague.com<\/a><\/u><\/i><\/b> or (267)764-4865.<\/i><\/b><\/p>\n

\n About Berger Montague<\/span>
<\/b>
\n Berger Montague<\/span> is one of the nation’s preeminent law firms focusing on complex civil litigation, class actions, and mass torts in federal and state courts throughout the United States<\/span>. With more than $2.4 billion<\/span> in 2025 post-trial judgments alone, the Firm is a leader in the fields of complex litigation, antitrust, consumer protection, defective products, environmental law, employment law, securities, and whistleblower cases, among many other practice areas. For over 55 years, Berger Montague<\/span> has played leading roles in precedent-setting cases and has recovered over $50 billion<\/span> for its clients and the classes they have represented. Berger Montague<\/span> is headquartered in Philadelphia<\/span> and has offices in Chicago<\/span>; Malvern, PA<\/span>; Minneapolis<\/span>; San Diego<\/span>; San Francisco<\/span>; Toronto, Canada<\/span>; Washington, D.C.<\/span>, and Wilmington, DE.<\/span><\/p>\n

\n For more information or to discuss your rights, please contact:
<\/b>
\n Andrew Abramowitz<\/span>
\n
\n Senior Counsel
<\/i>
\n Berger Montague<\/span>
\n
(215) 875-3015
aabramowitz@bergermontague.com<\/a><\/p>\n

\n Caitlin Adorni<\/span>
\n
\n Director of Portfolio & Institutional Client Monitoring Services
<\/i>
\n Berger Montague<\/span>
\n
(267) 764-4865
cadorni@bergermontague.com<\/a>\u00a0<\/p>\n

\n \"Cision\" View original content to download multimedia:https:\/\/www.prnewswire.com\/news-releases\/berger-montague-pc-investigating-claims-on-behalf-of-skye-bioscience-inc-nasdaq-skye-investors-after-class-action-filing-302632414.html<\/a><\/p>\n

SOURCE Berger Montague<\/span><\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire PHILADELPHIA , Dec. 3, 2025 \/PRNewswire\/ — National plaintiffs’ law firm Berger Montague PC\u00a0announces that a class action lawsuit has been filed against Skye Bioscience, Inc. (NASDAQ: SKYE) (“Skye” or the “Company”) on behalf of investors who purchased or otherwise acquired Skye securities during the period of\u00a0November 4, 2024 through October 3, 2025(the “Class Period”), inclusive. Investor Deadline: Investors who purchased Skye\u00a0securities during the Class Period may, no later than January 16, 2026, seek to be appointed as a lead plaintiff representative of the class. To learn your rights,\u00a0CLICK HERE. Skye, headquartered in San Diego, is a clinical-stage biotechnology company developing treatments for obesity and metabolic diseases. The complaint asserts that, throughout the Class Period, Defendants failed to … <\/p>\n

Continue reading “Berger Montague PC Investigating Claims on Behalf of Skye Bioscience, Inc. (NASDAQ: SKYE) Investors After Class Action Filing”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-916054","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nBerger Montague PC Investigating Claims on Behalf of Skye Bioscience, Inc. (NASDAQ: SKYE) Investors After Class Action Filing - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/berger-montague-pc-investigating-claims-on-behalf-of-skye-bioscience-inc-nasdaq-skye-investors-after-class-action-filing\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Berger Montague PC Investigating Claims on Behalf of Skye Bioscience, Inc. (NASDAQ: SKYE) Investors After Class Action Filing - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire PHILADELPHIA , Dec. 3, 2025 \/PRNewswire\/ — National plaintiffs’ law firm Berger Montague PC\u00a0announces that a class action lawsuit has been filed against Skye Bioscience, Inc. (NASDAQ: SKYE) (“Skye” or the “Company”) on behalf of investors who purchased or otherwise acquired Skye securities during the period of\u00a0November 4, 2024 through October 3, 2025(the “Class Period”), inclusive. Investor Deadline: Investors who purchased Skye\u00a0securities during the Class Period may, no later than January 16, 2026, seek to be appointed as a lead plaintiff representative of the class. To learn your rights,\u00a0CLICK HERE. Skye, headquartered in San Diego, is a clinical-stage biotechnology company developing treatments for obesity and metabolic diseases. The complaint asserts that, throughout the Class Period, Defendants failed to … Continue reading "Berger Montague PC Investigating Claims on Behalf of Skye Bioscience, Inc. (NASDAQ: SKYE) Investors After Class Action Filing"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/berger-montague-pc-investigating-claims-on-behalf-of-skye-bioscience-inc-nasdaq-skye-investors-after-class-action-filing\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-04T00:09:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/232479\/berger_montague.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/berger-montague-pc-investigating-claims-on-behalf-of-skye-bioscience-inc-nasdaq-skye-investors-after-class-action-filing\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/berger-montague-pc-investigating-claims-on-behalf-of-skye-bioscience-inc-nasdaq-skye-investors-after-class-action-filing\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Berger Montague PC Investigating Claims on Behalf of Skye Bioscience, Inc. (NASDAQ: SKYE) Investors After Class Action Filing\",\"datePublished\":\"2025-12-04T00:09:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/berger-montague-pc-investigating-claims-on-behalf-of-skye-bioscience-inc-nasdaq-skye-investors-after-class-action-filing\\\/\"},\"wordCount\":432,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/berger-montague-pc-investigating-claims-on-behalf-of-skye-bioscience-inc-nasdaq-skye-investors-after-class-action-filing\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/232479\\\/berger_montague.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/berger-montague-pc-investigating-claims-on-behalf-of-skye-bioscience-inc-nasdaq-skye-investors-after-class-action-filing\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/berger-montague-pc-investigating-claims-on-behalf-of-skye-bioscience-inc-nasdaq-skye-investors-after-class-action-filing\\\/\",\"name\":\"Berger Montague PC Investigating Claims on Behalf of Skye Bioscience, Inc. (NASDAQ: SKYE) Investors After Class Action Filing - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/berger-montague-pc-investigating-claims-on-behalf-of-skye-bioscience-inc-nasdaq-skye-investors-after-class-action-filing\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/berger-montague-pc-investigating-claims-on-behalf-of-skye-bioscience-inc-nasdaq-skye-investors-after-class-action-filing\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/232479\\\/berger_montague.jpg\",\"datePublished\":\"2025-12-04T00:09:29+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/berger-montague-pc-investigating-claims-on-behalf-of-skye-bioscience-inc-nasdaq-skye-investors-after-class-action-filing\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/berger-montague-pc-investigating-claims-on-behalf-of-skye-bioscience-inc-nasdaq-skye-investors-after-class-action-filing\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/berger-montague-pc-investigating-claims-on-behalf-of-skye-bioscience-inc-nasdaq-skye-investors-after-class-action-filing\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/232479\\\/berger_montague.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/232479\\\/berger_montague.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/berger-montague-pc-investigating-claims-on-behalf-of-skye-bioscience-inc-nasdaq-skye-investors-after-class-action-filing\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Berger Montague PC Investigating Claims on Behalf of Skye Bioscience, Inc. (NASDAQ: SKYE) Investors After Class Action Filing\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Berger Montague PC Investigating Claims on Behalf of Skye Bioscience, Inc. (NASDAQ: SKYE) Investors After Class Action Filing - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/berger-montague-pc-investigating-claims-on-behalf-of-skye-bioscience-inc-nasdaq-skye-investors-after-class-action-filing\/","og_locale":"en_US","og_type":"article","og_title":"Berger Montague PC Investigating Claims on Behalf of Skye Bioscience, Inc. (NASDAQ: SKYE) Investors After Class Action Filing - Market Newsdesk","og_description":"PR Newswire PHILADELPHIA , Dec. 3, 2025 \/PRNewswire\/ — National plaintiffs’ law firm Berger Montague PC\u00a0announces that a class action lawsuit has been filed against Skye Bioscience, Inc. (NASDAQ: SKYE) (“Skye” or the “Company”) on behalf of investors who purchased or otherwise acquired Skye securities during the period of\u00a0November 4, 2024 through October 3, 2025(the “Class Period”), inclusive. Investor Deadline: Investors who purchased Skye\u00a0securities during the Class Period may, no later than January 16, 2026, seek to be appointed as a lead plaintiff representative of the class. To learn your rights,\u00a0CLICK HERE. Skye, headquartered in San Diego, is a clinical-stage biotechnology company developing treatments for obesity and metabolic diseases. The complaint asserts that, throughout the Class Period, Defendants failed to … Continue reading \"Berger Montague PC Investigating Claims on Behalf of Skye Bioscience, Inc. (NASDAQ: SKYE) Investors After Class Action Filing\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/berger-montague-pc-investigating-claims-on-behalf-of-skye-bioscience-inc-nasdaq-skye-investors-after-class-action-filing\/","og_site_name":"Market Newsdesk","article_published_time":"2025-12-04T00:09:29+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/232479\/berger_montague.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/berger-montague-pc-investigating-claims-on-behalf-of-skye-bioscience-inc-nasdaq-skye-investors-after-class-action-filing\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/berger-montague-pc-investigating-claims-on-behalf-of-skye-bioscience-inc-nasdaq-skye-investors-after-class-action-filing\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Berger Montague PC Investigating Claims on Behalf of Skye Bioscience, Inc. (NASDAQ: SKYE) Investors After Class Action Filing","datePublished":"2025-12-04T00:09:29+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/berger-montague-pc-investigating-claims-on-behalf-of-skye-bioscience-inc-nasdaq-skye-investors-after-class-action-filing\/"},"wordCount":432,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/berger-montague-pc-investigating-claims-on-behalf-of-skye-bioscience-inc-nasdaq-skye-investors-after-class-action-filing\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/232479\/berger_montague.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/berger-montague-pc-investigating-claims-on-behalf-of-skye-bioscience-inc-nasdaq-skye-investors-after-class-action-filing\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/berger-montague-pc-investigating-claims-on-behalf-of-skye-bioscience-inc-nasdaq-skye-investors-after-class-action-filing\/","name":"Berger Montague PC Investigating Claims on Behalf of Skye Bioscience, Inc. (NASDAQ: SKYE) Investors After Class Action Filing - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/berger-montague-pc-investigating-claims-on-behalf-of-skye-bioscience-inc-nasdaq-skye-investors-after-class-action-filing\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/berger-montague-pc-investigating-claims-on-behalf-of-skye-bioscience-inc-nasdaq-skye-investors-after-class-action-filing\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/232479\/berger_montague.jpg","datePublished":"2025-12-04T00:09:29+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/berger-montague-pc-investigating-claims-on-behalf-of-skye-bioscience-inc-nasdaq-skye-investors-after-class-action-filing\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/berger-montague-pc-investigating-claims-on-behalf-of-skye-bioscience-inc-nasdaq-skye-investors-after-class-action-filing\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/berger-montague-pc-investigating-claims-on-behalf-of-skye-bioscience-inc-nasdaq-skye-investors-after-class-action-filing\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/232479\/berger_montague.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/232479\/berger_montague.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/berger-montague-pc-investigating-claims-on-behalf-of-skye-bioscience-inc-nasdaq-skye-investors-after-class-action-filing\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Berger Montague PC Investigating Claims on Behalf of Skye Bioscience, Inc. (NASDAQ: SKYE) Investors After Class Action Filing"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/916054","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=916054"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/916054\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=916054"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=916054"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=916054"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}